| Rachelle A Rose, PHD | |
|
49 E 200 S, Northern Utah Mental Counseling, Clearfield, UT 84015-1047 | |
| (801) 779-0095 | |
| (801) 779-0255 |
| Full Name | Rachelle A Rose |
|---|---|
| Gender | Female |
| Speciality | |
| Experience | Years |
| Location | 49 E 200 S, Clearfield, Utah |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265448104 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 5712578-2501-2014092 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rachelle A Rose, PHD 49 E 200 S, Northern Utah Mental Counseling, Clearfield, UT 84015-1047 Ph: (801) 779-0095 | Rachelle A Rose, PHD 49 E 200 S, Northern Utah Mental Counseling, Clearfield, UT 84015-1047 Ph: (801) 779-0095 |
News Archive
All of us who have been at this task before understand three important realities: One, no president who has launched such an effort unsuccessfully has ever been able to relaunch; two, the Senate legislation, at least, has been the product of much bipartisan effort over the last several years, even though no Republican senators voted for it, and three, the status quo costs and quality of this country's health care system are totally unacceptable - to the health care industry and to those who depend on it (Dave Durenberger, 2/18).
CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.
Republican lawmakers in a handful of states are opening another front in the war against President Obama's health care overhaul, seizing on the hot-button issue of birth control with bills that would allow insurance companies to ignore new federal rules requiring them to cover contraception. Measures introduced recently in Idaho, Missouri and Arizona would go beyond religious nonprofits and expand exemptions to secular insurers or businesses that object to covering contraception, abortion and sterilization.
Genzyme Corporation has announced that its Premarket Approval (PMA) application supplement for Synvisc-One (hylan G-F 20) will be discussed this Tuesday, December 9th, at a public meeting of the FDA's Orthopaedic and Rehabilitation Devices Advisory Committee in Gaithersburg, Maryland.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
› Verified 6 days ago
Rondi Mattson, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1785 East 1450 South, Suite 237, Clearfield, UT 84015 Phone: 801-525-1131 Fax: 801-525-1181 | |
John D Perovich, PSYD PLLC Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1785 E 1450 S Ste 250, Clearfield, UT 84015 Phone: 801-773-0535 Fax: 801-773-0536 | |
David Newbold, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 370 S 500 E, Suite 180, Clearfield, UT 84015 Phone: 801-776-1954 Fax: 801-774-9602 | |
Gerald E. Manwill, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1105 S State St, Clearfield, UT 84015 Phone: 801-721-8050 |